Partnering opportunity

Methods and panels to differentiate between stroke subtypes, diseases or brain damages through nasal exudate samples

Summary

Spanish researchers working in analytical chemistry and neurology have developed a new way of differentiating between stroke subtypes, diseases or brain damages through biomarkers from the central nervous system (CNS), by analyzing non-invasive samples (nasal exudate), in a quick, simple and painless way. Companies in the biotechnology and pharmacy fields, as well as in medicine and clinical diagnosis, are sought to develop applications of the described invention under license agreements.

Partner sought

Type of partner sought: industry. Specific area of activity of the partner: companies working in the biotechnology and pharmacy fields, as well as in medicine and clinical diagnosis. Task to be performed: development of applications of the described invention.

Description

The current diagnostic evaluation of acute stroke depends largely on neuroimaging techniques, such as computed tomography (CT) and brain magnetic resonance imaging (MRI). Although neuroimaging provides valuable diagnostic information, it is not always available, it requires specific infrastructure, considerable resources and specialized personnel, and sometimes it is not possible to do it on time. Other current solutions involve complex, invasive and slow procedures on the patient. Researchers from a Spanish university working in Analytical Chemistry and Neurology provide new methods and panels to differentiate between stroke subtypes, diseases or brain damage through biomarkers from the central nervous system (CNS), by analyzing samples of nasal exudate. The existence of a cerebral lymphatic drainage through the cribriform plate of the ethmoid bone could imply the presence in the nasal secretion of biomarkers that warn of the occurrence of certain cerebral episodes, neurological diseases or CNS events. The methods include analyzing a biological sample of nasal exudate to determine the concentration of one or more biomarkers, and then correlating it with the occurrence of a cerebral episode. The panels comprise a plurality of biomarkers that come from a sample of nasal exudate from the subject. The analytical procedures comprise means for non-invasive extraction of the sample and a detection system. The invention is applicable in the biotechnology and pharmacy fields, as well as in medicine and clinical diagnosis. It is also of great interest for the search for biomarkers that allow the study of other diseases such as Alzheimer's or Parkinson's or processes such as aging, closely related to failures in the drainage of proteins or other products of brain metabolism. The researchers would like to reach license agreements with companies operating in the above-mentioned fields with the aim to develop applications of the described technology.

Advantages and innovations

• The biomarkers are quantified from the CNS in nasal exudate, which contains CNS information thanks to cerebral lymphatic drainage that allows species to pass through the cribriform plate to the nasal mucosa. Through this invention it is shown for the first time that nasal exudate samples are suitable for obtaining information from the CNS. Since there is high anatomical proximity, the biomarker dilution is not high. • Nasal exudate is easy to obtain from a patient through quick, simple, painless and minimally invasive extraction processes. It is not necessary therefore that the subject is at the hospital. In addition, qualified personnel are not required for sampling (unlike what happens with, for example, a lumbar puncture to extract cerebrospinal fluid). • The invention also allows rapid therapeutic and logistic decisions. • It allows differentiating between ischemic and haemorrhagic strokes. • Metals or proteins can be used as biomarkers. The use of metallic biomarkers avoids the use of biological reagents and the performance of immunoassays, which normally require a longer procedure. • The invention provides techniques and technology that offer homogeneous and extraordinarily reliable results.

Development stage

Available for demonstration

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted


Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company